加速心脏电生理产品国产替代，「艾科脉医疗」完成超亿元Pre-B轮融资｜早起看早期

Core Viewpoint - Aikoma Medical has achieved significant revenue in its first year of commercialization, with several million yuan in earnings, following a successful over 100 million yuan Pre-B round financing aimed at accelerating the development and commercialization of its innovative cardiac electrophysiology technologies [4][7]. Group 1: Company Overview - Aikoma Medical focuses on the cardiac electrophysiology sector, particularly in developing pulse field ablation (PFA) technology, which selectively targets myocardial cells without damaging surrounding tissues [4][5]. - The company has established a comprehensive product matrix that includes a three-dimensional mapping system and a range of electrophysiological consumables [4][6]. - Aikoma Medical's PFA system has achieved a 100% immediate pulmonary vein isolation rate during procedures, with a 12-month follow-up success rate of 87.7% [6][7]. Group 2: Technology and Innovation - The PFA system features a unique variable circle diameter design to accommodate various clinical scenarios, enhancing its adaptability [8]. - Aikoma Medical has developed an intelligent algorithm to monitor catheter positioning, improving the effectiveness of the ablation process [6]. - The company is leveraging AI technology to process vast amounts of surgical data, enhancing the precision of three-dimensional cardiac models and simplifying surgical procedures [7][8]. Group 3: Market Potential and Investment - The global cardiovascular market is the second largest medical device market, with cardiac electrophysiology experiencing over 20 years of continuous growth [4]. - Investors recognize the broad market potential for PFA technology, which is becoming a mainstream treatment in the cardiac electrophysiology field [8]. - Aikoma Medical's products have been implemented in nearly 100 hospitals nationwide, with significant market access facilitated by successful procurement processes in regions like Beijing [7].